Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Overview

Latest Semaglutide News and Research

Innovative genome editing approach could be the key to lifelong effective weight management

Innovative genome editing approach could be the key to lifelong effective weight management

New study identifies factors linked to successful weight loss using GLP-1RAs

New study identifies factors linked to successful weight loss using GLP-1RAs

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

Newer, more effective diabetes drugs reach only a fraction of patients

Newer, more effective diabetes drugs reach only a fraction of patients

Glycogen metabolism in neurons emerges as key to fighting Alzheimer's

Glycogen metabolism in neurons emerges as key to fighting Alzheimer's

Coffee’s hidden compounds could help fight type 2 diabetes

Coffee’s hidden compounds could help fight type 2 diabetes

Tummy tuck patients continue losing weight years after surgery

Tummy tuck patients continue losing weight years after surgery

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

New guidance helps GPs manage patients using weight loss drugs

New guidance helps GPs manage patients using weight loss drugs

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Diabetes drug semaglutide shows promise in reducing dementia risk

Diabetes drug semaglutide shows promise in reducing dementia risk

Experimental drug promotes weight loss by heating fat instead of suppressing appetite

Experimental drug promotes weight loss by heating fat instead of suppressing appetite

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

Cagrilintide and semaglutide together drive record weight loss in global trial

Cagrilintide and semaglutide together drive record weight loss in global trial

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

New oral drug shows promise for type 2 diabetes and obesity without side effects

New oral drug shows promise for type 2 diabetes and obesity without side effects

Diabetes medication shows promise in cutting migraine days by more than half

Diabetes medication shows promise in cutting migraine days by more than half

New ACC guidance helps incorporate pharmacologic weight management strategies into cardiovascular care

New ACC guidance helps incorporate pharmacologic weight management strategies into cardiovascular care

How early-life factors raise lifelong diabetes risks in youth

How early-life factors raise lifelong diabetes risks in youth

Oxytocin stimulates pancreatic hormones to improve insulin secretion

Oxytocin stimulates pancreatic hormones to improve insulin secretion

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.